18/09/2026 CHMP recommended EU approval of Roche’s Ocrevus for children and adolescents with RMS Novartis’ Cosentyx® received a positive CHMP opinion for PMR Klygefa recommended for EU approval for gMG Alfasigma’s filgotinib received a positive CHMP opinion for axSpA CHMP recommended EU approval of Roche’s Ocrevus for children and adolescents with RMS (Ref) The EMA’s CHMP recommended approval of Ocrevus® (ocrelizumab; CD20 inhibitor) intravenous infusion for patients aged ≥10